Browse our 650+ Publications
Latest Publications
Persistence of intrathecal oligoclonal B cells and IgG in multiple sclerosis
Tomescu-Baciu et al.
Journal of Neuroimmunology
May 2019
Authors and Affiliates
Tomescu-Baciu A1, Johansen JN1, Holmøy T2, Greiff V3, Stensland M4, de Souza GA4, Vartdal F1, Lossius A5; 1
Department of Immunology and Transfusion Medicine, Faculty of Medicine, University of Oslo and Oslo University Hospital Rikshospitalet, Oslo, Norway.
2
Department of Neurology, Akershus University Hospital, Lørenskog, Norway; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
3
Department of Immunology and Transfusion Medicine, Faculty of Medicine, University of Oslo and Oslo University Hospital Rikshospitalet, Oslo, Norway; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
4
Department of Immunology and Transfusion Medicine, Faculty of Medicine, University of Oslo and Oslo University Hospital Rikshospitalet, Oslo, Norway; Proteomics Core Facility, Oslo University Hospital Rikshospitalet, NO-0372 Oslo, Norway.
5
Department of Immunology and Transfusion Medicine, Faculty of Medicine, University of Oslo and Oslo University Hospital Rikshospitalet, Oslo, Norway; Department of Neurology, Akershus University Hospital, Lørenskog, Norway. Electronic address: andreas.lossius@medisin.uio.no.
Human urothelial bladder cancer generates a clonal immune response: The results of T-cell receptor sequencing
Sankin et al.
Urologic Oncology
May 2019
Authors and Affiliates
Sankin A1, Chand D2, Schoenberg M3, Zang X2.
1
Department of Urology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY. Electronic address: asankin@montefiore.org.
2
Department of Urology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY; Department of Microbiology and Immunology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY.
3
Department of Urology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
Voorwerk et al.
Nature Medicine
May 2019
Authors and Affiliates
Voorwerk L1, Slagter M1,2,3, Horlings HM4, Sikorska K5, van de Vijver KK4,6, de Maaker M7, Nederlof I7, Kluin RJC8, Warren S9, Ong S9, Wiersma TG10, Russell NS10, Lalezari F11, Schouten PC7, Bakker NAM3,12, Ketelaars SLC1, Peters D13, Lange CAH11, van Werkhoven E5, van Tinteren H5, Mandjes IAM5, Kemper I14, Onderwater S14, Chalabi M1,15, Wilgenhof S14, Haanen JBAG1,14, Salgado R16,17, de Visser KE3,12, Sonke GS14, Wessels LFA2,3, Linn SC7,14, Schumacher TN1,3, Blank CU1,14, Kok M18,19.
1
Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
2
Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
3
Oncode Institute, Utrecht, the Netherlands.
4
Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
5
Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
6
Department of Pathology, Ghent University Hospital, Ghent, Belgium.
7
Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
8
Genomics Core Facility, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
9
NanoString Technologies, Inc., Seattle, WA, USA.
10
Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
11
Department of Radiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
12
Division of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
13
Core Facility Molecular Pathology & Biobanking, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
14
Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
15
Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
16
Department of Pathology, GZA-ZNA Ziekenhuizen, Antwerp, Belgium.
17
Division of Research, Peter Mac Callum Cancer Center, Melbourne, Victoria, Australia.
18
Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. m.kok@nki.nl.
19
Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. m.kok@nki.nl.
Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects
Klotz et al.
Science Translational Medicine
May 2019
Authors and Affiliates
Klotz L1, Eschborn M2, Lindner M2, Liebmann M2, Herold M2, Janoschka C2, Torres Garrido B2, Schulte-Mecklenbeck A2, Gross CC2, Breuer J2, Hundehege P2, Posevitz V2, Pignolet B3, Nebel G4, Glander S5, Freise N6, Austermann J6, Wirth T2, Campbell GR7, Schneider-Hohendorf T2, Eveslage M8, Brassat D3, Schwab N2, Loser K9, Roth J6, Busch KB4, Stoll M5,10, Mahad DJ7, Meuth SG2, Turner T11, Bar-Or A12, Wiendl H2,13;
1
University Hospital Münster, Department of Neurology with Institute of Translational Neurology, 48149 Münster, Germany. luisa.klotz@ukmuenster.de.
2
University Hospital Münster, Department of Neurology with Institute of Translational Neurology, 48149 Münster, Germany.
3
CRC-SEP, Neurosciences Department, Toulouse University Hospital and INSERM U1043 - CNRS UMR 5282, Centre de Physiopathologie Toulouse-Purpan, Université Toulouse III, 31300 Toulouse, France.
4
University of Münster, Institute of Molecular Cell Biology, 48149 Münster, Germany.
5
University of Münster, Department of Genetic Epidemiology, 48149 Münster, Germany.
6
University of Münster, Department of Immunology, 48149 Münster, Germany.
7
University of Edinburgh, Centre for Clinical Brain Sciences, EH8 9YL Edinburgh, UK.
8
University of Münster, Institute of Biostatistics and Clinical Research, 48149 Münster, Germany.
9
University Hospital Münster, Department of Dermatology, 48149 Münster, Germany.
10
Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, 6229 ER Maastricht, Netherlands.
11
Sanofi Genzyme, Cambridge, MA 02142, USA.
12
Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
13
Brain and Mind Centre, Medical Faculty, University of Sydney, Sydney, Camperdown, NSW 2050, Australia.
A novel human IL2RB mutation results in T and NK cell-driven immune dysregulation
Fernandez et al.
Journal of Experimental Medicine
April 2019
Authors and Affiliates
Fernandez IZ#1, Baxter RM#1, Garcia-Perez JE1, Vendrame E2, Ranganath T2, Kong DS1, Lundquist K3, Nguyen T4, Ogolla S1, Black J5, Galambos C5, Gumbart JC3, Dawany N6, Kelsen JR7, de Zoeten EF4, Quinones R8, Eissa H8, Verneris MR8, Sullivan KE9, Rochford R1, Blish CA2,10, Kedl RM#11, Dutmer CM#12, Hsieh EWY#13,14;
1
Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO.
2
Department of Medicine, Stanford University School of Medicine, Stanford, CA.
3
School of Physics, Georgia Institute of Technology, Atlanta, GA.
4
Department of Pediatrics, Division of Gastroenterology, Hepatology and Nutrition, University of Colorado School of Medicine, Digestive Health Institute, Children's Hospital Colorado, Aurora, CO.
5
Department of Pathology and Laboratory Medicine, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, CO.
6
Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, PA.
7
Department of Pediatrics, Division of Gastroenterology, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
8
Department of Pediatrics, Division of Hematology/Oncology and Blood and Marrow Transplantation, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, CO.
9
Department of Pediatrics, Division of Allergy and Immunology, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
10
Immunology Program, School of Medicine, Stanford University, Stanford, CA.
11
Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO ross.kedl@ucdenver.edu.
12
Department of Pediatrics, Section of Allergy and Immunology, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, CO cullen.dutmer@childrenscolorado.org.
13
Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO elena.hsieh@ucdenver.edu.
14
Department of Pediatrics, Section of Allergy and Immunology, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, CO.
#
Contributed equally
Rational design of anti-GITR-based combination immunotherapy
Zappasodi et al.
Nature Medicine
April 2019
Authors and Affiliates
Zappasodi R1,2, Sirard C3, Li Y1,2, Budhu S1, Abu-Akeel M1, Liu C1, Yang X1, Zhong H1, Newman W3, Qi J2,4, Wong P2,4, Schaer D1, Koon H5, Velcheti V6, Hellmann MD2,7,8, Postow MA7,8, Callahan MK2,7,8, Wolchok JD9,10,11,12, Merghoub T13,14,15;
Author information
1
Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
2
Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
3
Leap Therapeutics, Cambridge, MA, USA.
4
Immune Monitoring Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
5
Case Western Reserve University, Cleveland, OH, USA.
6
Department of Hematology and Oncology, New York University School of Medicine, New York, NY, USA.
7
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
8
Weill Cornell Medical College, New York, NY, USA.
9
Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA. wolchokj@mskcc.org.
10
Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA. wolchokj@mskcc.org.
11
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. wolchokj@mskcc.org.
12
Weill Cornell Medical College, New York, NY, USA. wolchokj@mskcc.org.
13
Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA. merghout@mskcc.org.
14
Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA. merghout@mskcc.org.
15
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. merghout@mskcc.org.
Immunogenic neoantigens derived from gene fusions stimulate T cell responses
Yang et al.
Nature Medicine
April 2019
Authors and Affiliates
Yang W1,2, Lee KW1, Srivastava RM2, Kuo F2, Krishna C3, Chowell D2, Makarov V2, Hoen D2, Dalin MG4, Wexler L5, Ghossein R6, Katabi N6, Nadeem Z7, Cohen MA7, Tian SK8, Robine N8, Arora K8, Geiger H8, Agius P8, Bouvier N9, Huberman K9, Vanness K9, Havel JJ1,2, Sims JS2, Samstein RM10, Mandal R2,7, Tepe J7, Ganly I7, Ho AL11, Riaz N2,10, Wong RJ7, Shukla N6, Chan TA12,13,14, Morris LGT15,16,17;
1
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
2
Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
3
Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
4
Department of Pediatrics, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden.
5
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
6
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
7
Department of Surgery (Head and Neck Service), Memorial Sloan Kettering Cancer Center, New York, NY, USA.
8
New York Genome Center, New York, NY, USA.
9
Integrated Genomics Operation, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
10
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
11
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
12
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. chant@mskcc.org.
13
Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA. chant@mskcc.org.
14
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. chant@mskcc.org.
15
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. morrisl@mskcc.org.
16
Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA. morrisl@mskcc.org.
17
Department of Surgery (Head and Neck Service), Memorial Sloan Kettering Cancer Center, New York, NY, USA. morrisl@mskcc.org.
Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States
Wei et al.
Immunity
April 2019
Authors and Affiliates
Wei SC1, Sharma R2, Anang NAS1, Levine JH3, Zhao Y4, Mancuso JJ1, Setty M3, Sharma P5, Wang J4, Pe'er D6, Allison JP7; 1Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
2
Computational and Systems Biology Program, Sloan Kettering Institute, New York, NY 10065, USA; Department of Applied Physics and Applied Mathematics, Columbia University, New York, NY 10027, USA.
3
Computational and Systems Biology Program, Sloan Kettering Institute, New York, NY 10065, USA.
4
Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
5
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Parker Institute for Cancer Immunotherapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
6
Computational and Systems Biology Program, Sloan Kettering Institute, New York, NY 10065, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
7
Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Parker Institute for Cancer Immunotherapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: jallison@mdanderson.org.
A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL-2-Receptor Beta/Gamma (βγ)-Biased Cytokine, in Patients With Advanced or Metastatic Solid Tumors
Bentebibel et al.
Cancer Discovery
April 2019
Authors and Affiliates
Salah-Eddine Bentebibel1*, Michael E. Hurwitz2*, Chantale Bernatchez1*, Cara Haymaker1, Courtney W. Hudgens1, Harriet M. Kluger2, Michael T. Tetzlaff1, Mary A. Tagliaferri3, Jonathan Zalevsky3, Ute Hoch3, Christie Fanton3, Sandra Aung3, Patrick Hwu1, Brendan D. Curti4, Nizar M. Tannir1, Mario Sznol2, Adi Diab1;
1. The University of Texas MD Anderson Cancer Center, Houston, TX
2. Yale School of Medicine, New Haven, CT
3. Nektar Therapeutics, San Francisco, CA
4. Providence Cancer Institute and Earle A. Chiles Research Institute, Portland, OR
*These authors contributed equally